Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sandra J. Casak"'
Autor:
M. Naomi Horiba, Sandra J. Casak, Pallavi S. Mishra-Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery, Lola A. Fashoyin-Aje
Publikováno v:
Clin Cancer Res
The FDA approved nivolumab on May 20, 2021, for the adjuvant treatment of completely resected (negative margins) esophageal or gastroesophageal junction cancer (EC/GEJC) in patients who had residual pathologic disease following chemoradiotherapy. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f802b4c663add72d06c7d997013928d3
https://europepmc.org/articles/PMC9771915/
https://europepmc.org/articles/PMC9771915/
Autor:
Sandra J. Casak, Shan Pradhan, Lola A. Fashoyin-Aje, Yi Ren, Yuan-Li Shen, Yuan Xu, Edwin Chiu Yuen Chow, Ye Xiong, Jeanne Fourie Zirklelbach, Jiang Liu, Rosane Charlab, William F. Pierce, Nataliya Fesenko, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery
Publikováno v:
Clin Cancer Res
On August 25, 2021, the FDA approved ivosidenib for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma (CCA) as detected by an FDA-approved test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af40300243294b5f12940579ab82ce88
https://europepmc.org/articles/PMC9250596/
https://europepmc.org/articles/PMC9250596/
Autor:
David J. James Pinato, Xiaoxue Li, Pallavi Shruti Mishra-Kalyani, Antonio D'Alessio, Claudia A.M. Fulgenzi, Guo Wei, Julie A. Schneider, Donna Rivera, Richard Pazdur, Marc Robert Theoret, Sandra J. Casak, Steven Lemery, Ibilola Fashoyin, Alessio Cortellini, Lorraine Cheryl Pelosof
Publikováno v:
Journal of Clinical Oncology. 40:4089-4089
4089 Background: Immune checkpoint inhibitors (ICI) alone or in combination with tyrosine kinase (TKI) or VEGF pathway inhibitors (VEGFi) are therapeutic options in unresectable HCC (uHCC). Whether exposure to antibiotics (ATB), a consolidated advers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5527bce2cbb0d8394b364d11f572bcf7
https://doi.org/10.1200/jco.2022.40.16_suppl.4089
https://doi.org/10.1200/jco.2022.40.16_suppl.4089
Autor:
Jee Chung, Steven Lemery, Edwin C. Y. Chow, Sandra J. Casak, Amy E. McKee, Richard Pazdur, Sarah J Schrieber, Weishi Yuan, Thomas Gwise, Lisa Rodriguez, Anne M. Rowzee, Sue Lim, Chana Fuchs, Patricia Keegan
Publikováno v:
Clinical Cancer Research. 24:4365-4370
Passage of the Biologics Price Competition and Innovation Act of 2009 created an abbreviated licensure pathway for biosimilar products. The FDA approved ABP215 (MVASI, bevacizumab-awwb; Amgen) as a biosimilar to U.S.-licensed Avastin (bevacizumab; Ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd8ce03fc3b8891f169cf03f9a1826fa
https://doi.org/10.1158/1078-0432.ccr-18-0566
https://doi.org/10.1158/1078-0432.ccr-18-0566
Autor:
Rachel Novak, Michele Dougherty, Sarah Kennett, Sachia Khasar, Hongshan Li, Steven Lemery, Kun He, Patricia Keegan, Hong Zhao, Whitney Helms, Richard Pazdur, Runyan Jin, Hui Zhang, L. Zhang, Liang Zhao, Ibilola Fashoyin-Aje, Sandra J. Casak, Huanyu Chen
Publikováno v:
Clinical Cancer Research. 21:3372-3376
The FDA approved ramucirumab (CYRAMZA; Eli Lilly and Company) for previously treated patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma initially as monotherapy (April 21, 2014) and subsequently as combination th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7260a69dc1a56105c15ce8a26ed1c1e2
https://doi.org/10.1158/1078-0432.ccr-15-0600
https://doi.org/10.1158/1078-0432.ccr-15-0600
Autor:
María T. G. de Dávila, Julio Manzitti, Adriana Fandiño, Elsa C. Raslawski, Marcelo Scopinaro, Sandra J. Casak, Enrique Schvartzman, Guillermo L. Chantada
Publikováno v:
Pediatric Blood & Cancer. 44:455-460
Background Chemoreduction is used for the treatment of retinoblastoma in industrialized nations; however, there are fewer data from developing countries. Before the implementation of this program, radiotherapy was used in almost all preserved eyes. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6a9569a96ba8e30ca2a65e7408b16e5
https://doi.org/10.1002/pbc.20259
https://doi.org/10.1002/pbc.20259
Autor:
Sandra J. Casak, Adriana Fandiño, Guillermo L. Chantada, Enrique Schvartzman, Julio Manzitti, Gabriel Mato
Publikováno v:
Ophthalmic Genetics. 25:37-43
To report our experience with topotecan in children with relapsed/refractory metastatic and intraocular retinoblastoma.Topotecan was administered intravenously as a 30-min infusion at a dose of 2 mg/m2/d for five consecutive days and repeated after t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d445efcfb0b558bee37add5a1f1e081
https://doi.org/10.1076/opge.25.1.37.28996
https://doi.org/10.1076/opge.25.1.37.28996
Autor:
Sandra J Casak, Marceio J Scopinaro
Publikováno v:
The Lancet Oncology. 3:111-117
Summary The process of globalisation is affecting health and health care in Argentina, as it is in many other countries. The full extent of this effect is still unclear, but winners and losers in the world economy are emerging – not only different
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2282968f790a66cabde2d3f14b93593f
https://doi.org/10.1016/s1470-2045(02)00653-8
https://doi.org/10.1016/s1470-2045(02)00653-8
Publikováno v:
Journal of Clinical Oncology. 35:2544-2544
2544 Background: In new drug/biologics applications, safety data provided to FDA include serious adverse events (SAEs), defined as adverse events (AEs) resulting in death, life-threatening AE, inpatient hospitalization or prolongation of hospitalizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccce3c0551cd2d0f42dd606d6138eac3
https://doi.org/10.1200/jco.2017.35.15_suppl.2544
https://doi.org/10.1200/jco.2017.35.15_suppl.2544
Autor:
Sandra J. Casak, Richard Pazdur, Daniel L. Suzman, Amy E. McKee, Paul G. Kluetz, Ashley Flynn Ward, Leigh Marcus
Publikováno v:
Journal of Clinical Oncology. 35:e18236-e18236
e18236 Background: Breakthrough therapy designation is an FDA program intended to expedite the development of drugs and biologics that provide preliminary clinical evidence of a substantial improvement over existing therapies. The factors needed to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ca4e803f650d368e2df574b53f66d99
https://doi.org/10.1200/jco.2017.35.15_suppl.e18236
https://doi.org/10.1200/jco.2017.35.15_suppl.e18236